Latest Conference Articles

Phase 2 results have placed a novel EGFR exon 20 insertion inhibitors in the realm of possibilities for future treatment of previously-treated non–small cell lung cancer with EGFR exon 20 insertions in the tumor tissue.

New results from the TROPION-Lung02 trial highlight the potential of the antibody-drug conjugate datopotamab deruxtecan with pembrolizumab for patients with advanced non–small cell lung cancer.

The combination of avutometinib with defactinib elicited high activity in patients with recurrent low-grade serous ovarian cancer, according to data from RAMP 201.

Eftilagimod alpha plus pembrolizumab showed an overall response rate of over 25% in patients with metastatic head and neck squamous cell carcinoma treated in the phase 2 TACTI-002 study.

The use of maintenance niraparib therapy led to clinically meaningful improvement in progression-free survival, compared with placebo, in patients with newly diagnosed, advanced ovarian cancer.

Second-line maintenance therapy with niraparib improved overall survival in a BRCA gene wild-type population with recurrent ovarian cancer.

Treatment with axicabtagene ciloleucel in the second-line setting led to significant improvement in overall survival compared with high-dose therapy plus transplant in patients with early relapsed or refractory large B-cell lymphoma.

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

The investigational agent, ABBV-011, is showing promise, according to results from a phase 1 clinical trial.

According to Binod Dhakal, MD, ciltacabtagene autoleucel may become a new standard therapy for patients with lenalidomide (Revlimid)-refractory multiple myeloma.

Lasofoxifene in combination abemaciclib showed antitumor activity that was not compromised by co-occuring alterations that confer endocrine resistance.

A sustained overall survival benefit has been reported from the phase 3 TROPiCS-02 study.

The combination of doxorubicin, balstilimab, and zalifrelimab has some early signals of activity in both immune hot and cold sarcoma subtypes with manageable toxicity.

The primary end point was not reached in the phase 3 SOLSTICE study.

Patritumab deruxtecan treatment yielded efficacy results and was safe for patients with metastatic breast cancer.

Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.

Correlative work is ongoing following positive results from the phase 1 study of cabozantinib with nivolumab and ipilimumab.

In a phase 1 study, anti-tumor responses were induced with PRT811 treatment in patients with recurrent, high-grade glioma and advanced or metastatic uveal melanoma.

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.

New data show the promise for use of tovorafenib to reduce pre-treated pediatric patients with a low-grade glioma.

In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma setting, says Omid Hamid, MD.

Patients with non–small cell lung cancer who completed definitive surgery saw clinical benefits after being treated with neoadjuvant nivolumab and chemotherapy.

New findings with the gamma secretase inhibitor nirogacestat show pain reduction for patients with desmoid tumors.

Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.

Results from the DESTINY-CRC02 study showed that a lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.

New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.

Results from the TALAPRO-2 study highlight the potential for the first-line treatment of patients with homologous recombination repair altered metastatic castration-resistant prostate cancer.

When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.